Lifecore Biomedical, Inc.LFCRNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank28
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P28
Within normal range
vs 3Y Ago
-0.9x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -6.66% |
| Q2 2025 | 2.84% |
| Q1 2025 | 6.29% |
| Q4 2024 | -11.99% |
| Q3 2024 | 1.16% |
| Q2 2024 | -0.41% |
| Q1 2024 | 3.43% |
| Q4 2023 | -2.24% |
| Q3 2023 | -17.71% |
| Q2 2023 | 16.74% |
| Q1 2023 | 2.62% |
| Q4 2022 | -1.54% |
| Q3 2022 | 7.54% |
| Q2 2022 | 2.80% |
| Q1 2022 | 7.76% |
| Q4 2021 | -0.91% |
| Q3 2021 | -27.37% |
| Q2 2021 | 39.93% |
| Q1 2021 | -28.34% |
| Q4 2020 | 2.55% |
| Q3 2020 | -7.42% |
| Q2 2020 | -1.38% |
| Q1 2020 | -2.66% |
| Q4 2019 | 0.04% |
| Q3 2019 | -18.49% |
| Q2 2019 | 26.27% |
| Q1 2019 | 8.21% |
| Q4 2018 | -10.59% |
| Q3 2018 | -21.22% |
| Q2 2018 | 15.52% |
| Q1 2018 | -7.68% |
| Q4 2017 | 24.02% |
| Q3 2017 | -23.54% |
| Q2 2017 | 76.56% |
| Q1 2017 | 2.49% |
| Q4 2016 | 1.39% |
| Q3 2016 | 6.78% |
| Q2 2016 | -4.22% |
| Q1 2016 | 15.34% |
| Q4 2015 | -12.37% |